Home > Insider Trading > Filing (0000950170-24-081878)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1658247	Crinetics Pharmaceuticals Inc.	CRNX	Pharmaceutical Preparations (2834)	263744114

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1948238	Dana Pizzuti	C/O Crinetics Pharmaceuticals, Inc. 6055 Lusk Boulevard San Diego CA 92121	Chief Med And Dev Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-07-03	14,375	$16.89	42,882	No	4	M	Direct
Common Stock	Disposition	2024-07-03	14,375	$44.87	28,507	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (Right to Buy)	Disposition	2024-07-03	14,375	$0.00	14,375	$16.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
153,417		2032-10-10	No	4	M	Direct

Footnotes

The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.87 per share. The range of sales prices on the transaction date was $44.24 to $45.55 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Includes 721 shares acquired under the Issuer's Employee Stock Purchase Plan.
The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.